Innate Pharma S.A. Sponsored ADR Capital Expenditures

Capital Expenditures of IPHA for past 10 years: annual, quarterly and twelve month trailing (TTM) including Capital Expenditures growth rates and interactive chart. Capital expenditures, commonly known as Capex, are funds used by a company to acquire, upgrade, and maintain physical or intangible assets such as property, buildings, an industrial plant, technology, software or equipment. Capex is often used to undertake new projects or investments by the firm. A company must invest over its lifetime into productive assets to maintain its competitiveness and ensure its survival.

Highlights and Quick Summary

  • Capital Expenditures for the quarter ending June 29, 2020 was $-10.8 Million (a 658.86% increase compared to previous quarter)
  • Year-over-year quarterly Capital Expenditures increased by 948.13%
  • Annual Capital Expenditures for 2019 was $-73.2 Million (a 4308.08% increase from previous year)
  • Twelve month Capital Expenditures ending June 29, 2020 was $-3.84 Million
Trailing Capital Expenditures for the last four month:
29 Jun '20 — — —
$-3.84 Million — — —
Visit stockrow.com/IPHA for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Capital Expenditures of Innate Pharma S.A. Sponsored ADR

Most recent Capital Expendituresof IPHA including historical data for past 10 years.

Interactive Chart of Capital Expenditures of Innate Pharma S.A. Sponsored ADR

Innate Pharma S.A. Sponsored ADR Capital Expenditures for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 – – – $-10.81 –
2019 – – $-1.42 $-72.91 $-73.25
2018 $-1.03 – – – $-1.66

Business Profile of Innate Pharma S.A. Sponsored ADR

Sector: Healthcare
Industry: Biotechnology
Innate Pharma S.A., a biotechnology company, discovers and develops therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Monalizumab, an immune checkpoint inhibitor that is in Phase II clinical trial to treat advanced solid tumors comprising colorectal cancer, as well as head and neck cancer; Anti-Siglec-9, checkpoint inhibitor program, which is in preclinical stage for immuno-oncology; Lumoxiti (moxetumomab pasudotox-tdfk), a tumor antigen targeting solution for the treatment of hairy cell leukemia; and Lacutamab (IPH4102), an anti-KIR3DL2 humanized cytotoxicity-inducing antibody, which is in Phase II clinical trial for the treatment of cutaneous T-cell lymphoma. Its products also include IPH61, a bispecific NK cell engager, a preclinical solution for the generation and evaluation of up to two bispecific NK cell engagers; IPH43, a program that is in preclinical trial to develop anti-MICA/B therapeutic antibody in oncology; Avdoralimab/IPH5401, a therapeutic antibody, which is in Phase II clinical trial that binds and blocks C5a receptors expressed on subsets of myeloid-derived suppressor cells and neutrophils; IPH5201, a blocking antibody that is in Phase I clinical trial targeting the CD39 immunosuppressive pathway; and IPH5301, a CD-73-blocking antibody that is in preclinical trial for restoring a pro-inflammatory microenvironment. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, and Sanofi; and co-development and license agreement with MedImmune. The company was founded in 1999 and is headquartered in Marseille, France.
© stockrow.com